Royalty Pharma Raises 2026 Receipts Outlook After 9% Q3 Growth
Photo: TokenPost
Royalty Pharma raised its 2026 Portfolio Receipts outlook to $3.5 billion to $3.55 billion after third-quarter receipts rose 9%, while net income attributable to the company declined year over year. The new guidance is up from the company’s previous range of $3.4 billion to $3.5 billion. It includes expected Royalty Receipts growth of 10% to 11% and excludes new transactions and borrowings announced after Nov. 4. Portfolio Receipts, which totaled $890 million for the three months ended Sept. 30, include Royalty Receipts plus milestones and other contractual receipts.
Source: TokenPost
